FDA Calls Medicare ESA Coverage Decision “Generally Consistent” With Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA acknowledges confusion with dosing recommendations that it aims to clarify in revised labeling, agency advises Reps. Waxman and Stark.
You may also be interested in...
J&J Finds Silver Lining in CMS Reimbursement Decision On ESAs
Although disappointing, the CMS decision to eliminate Medicare reimbursement for some ESA uses has created an environment of greater certainty for planning purposes, J&J exec says.
J&J Finds Silver Lining in CMS Reimbursement Decision On ESAs
Although disappointing, the CMS decision to eliminate Medicare reimbursement for some ESA uses has created an environment of greater certainty for planning purposes, J&J exec says.
Requests To Reopen Medicare ESA Policy Are Not Yet Persuasive To CMS
Agency advises stakeholders that they must present new data or analysis that current data was materially misinterpreted in order to gain a reconsideration of the erythropoeisis-stimulating agents coverage policy.